Back to Resources

SCORR Marketing and Applied Clinical Trials surveyed employees of drug sponsors (including pharmaceutical and biotech companies), research sites, academic institutions and service providers to understand collaboration in R&D.

While many have turned to collaborative R&D as a way to speed drug development projects, reduce costs and support federal and academic research, others see collaboration as a risk.

Learn more about the prevalence of collaborative R&D and read what those involved had to say about:

  • Why organizations engage in R&D collaborations
  • Why these arrangements are becoming more popular
  • The pros and cons of these joint efforts
  • Which stakeholders are receptive to R&D partnerships
  • Industry beliefs about what research should be done collaboratively

Read the Report